Last week Weill Cornell researcher Dr. Ari Melnick sat down with Targeted Oncology to briefly summarize the potential of EZH2 in treating diffuse large B-cell lymphoma.
Tag: Weill Cornell Lymphoma Program
Two Newly Opened Clinical Trials Evaluate Idelalisib in Indolent non-Hodgkin Lymphoma
The Weill Cornell Lymphoma Program has recently opened two clinical trials evaluating the experimental drug idelalisib in previously treated indolent non-Hodgkin lymphomas (iNHL). The sponsor of the trials is Gilead Sciences. The principal investigator at Weill Cornell is Dr. Peter Martin. For more information about the studies please call Amelyn Rodriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.
Idelalisib (GS-1101, previously CAL-101) works by blocking some of the cell functions that cause iNHL to grow and survive.
Gilead 0124: Idelalisib in Combination With Rituximab
This study evaluates the effectiveness of idelalisib combined with rituximab in treating iNHL. Rituximab is FDA-approved for treating iNHL. It is possible that giving rituximab together with idelalisib may have more activity against iNHL than giving rituximab alone.
Key Eligibility
- Men and women age 18 and older
- B-cell indolent non-Hodgkin lymphoma (iNHL)
- Have received prior therapy containing anti-CD20 antibody
- iNHL is not refractory to rituximab
Click here for a detailed summary of this trial.
Gilead 0125: Idelalisib in Combination With Bendamustine and Rituximab
Update: this study is closed to enrollment.
This study evaluates the effectiveness of idelalisib combined with bendamustine and rituximab. Rituximab and bendamustine are FDA-approved for treating iNHL. It is possible that giving rituximab and bendamustine together with idelalisib is more effective in treating iNHL than giving rituximab and bendamustine alone.
Key Eligibility
- Men and women age 18 and older
- B-cell indolent non-Hodgkin lymphoma
- Have received prior therapy containing anti-CD20 antibody and chemotherapy
- iNHL is not refractory to bendamustine
Click here for a detailed summary of this trial.
New Clinical Trial: Ibrutinib in Refractory Follicular Lymphoma
The Weill Cornell Lymphoma Program has recently opened a clinical trial evaluating ibrutinib in men and women with refractory follicular lymphoma. The study sponsor is Janssen Pharmaceuticals, and the principal investigator at Weill Cornell is Dr. Peter Martin. For more information about the study, please call Amelyn Rodriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.
Key Eligibility
- Age 18 and older
- Refractory follicular lymphoma
- Previously treated with at least 2 prior lines of therapy
- Did not respond to last prior therapy
- Detailed eligibility reviewed when you contact the study team
Study Details
The purpose of the study is to evaluate the response to treatment with the experimental drug ibrutinib, also called PCI-32765. Ibrutinib is an oral drug that inhibits the enzyme Bruton’s Tyrosine Kinase (BTK), decreasing the ability of lymphoma cells to grow and survive.
Treatment Plan
All study participants will receive ibrutinib; there is no placebo. Participants will take 4 capsules by mouth once every day. Participants will continue taking ibrutinib as long as they are responding to treatment and not experiencing unacceptable side effects.
Click here to view all current lymphoma trials at Weill Cornell Medical College.
